Jay Stout
Chief Tech/Sci/R&D Officer at IMMUNOVANT, INC.
Net worth: 4 M $ as of 29/04/2024
Profile
Jay Stout is currently the Chief Technology Officer at Immunovant, Inc. He previously worked as the Chief Technical Officer at Immunomedics, Inc. and as the Senior Vice President-Technical Operations at Versartis, Inc. Stout received his undergraduate and graduate degrees from the University of Iowa and his doctorate from The University of Nebraska-Lincoln.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
IMMUNOVANT INC
0.10% | 23/04/2024 | 147,739 ( 0.10% ) | 4 M $ | 29/04/2024 |
Jay Stout active positions
| Companies | Position | Start |
|---|---|---|
| IMMUNOVANT, INC. | Chief Tech/Sci/R&D Officer | 31/03/2023 |
Former positions of Jay Stout
| Companies | Position | End |
|---|---|---|
| IMMUNOMEDICS, INC. | Chief Tech/Sci/R&D Officer | - |
Versartis, Inc.
 Versartis, Inc. Pharmaceuticals: MajorHealth Technology Versartis, Inc. is an endocrine-focused biopharmaceutical company, which engages in the research and development of pharmaceutical products. Its portfolio includes Somavartan and XTEN TEchnology which target the endocrine disorders and growth hormone deficiencies. The company was founded by Jeffrey L. Cleland, Mark de Boer, Willem Stemmer, Volker Schellenberger, and Joshua Silverman on December 10, 2008 and is headquartered in Menlo Park, CA. | Chief Tech/Sci/R&D Officer | - |
Training of Jay Stout
| The University of Nebraska-Lincoln | Doctorate Degree |
| University of Iowa | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| IMMUNOVANT, INC. | Health Technology |
| Private companies | 2 |
|---|---|
Versartis, Inc.
Versartis, Inc. Pharmaceuticals: MajorHealth Technology Versartis, Inc. is an endocrine-focused biopharmaceutical company, which engages in the research and development of pharmaceutical products. Its portfolio includes Somavartan and XTEN TEchnology which target the endocrine disorders and growth hormone deficiencies. The company was founded by Jeffrey L. Cleland, Mark de Boer, Willem Stemmer, Volker Schellenberger, and Joshua Silverman on December 10, 2008 and is headquartered in Menlo Park, CA. | Health Technology |
Immunomedics, Inc.
 Immunomedics, Inc. BiotechnologyHealth Technology Immunomedics, Inc. researching, developing, manufacturing, and marketing biopharmaceutical products. It focuses on monoclonal antibody-based products for the targeted treatment of cancer. The company was founded by David M. Goldenberg in July 1982 and is headquartered in Morris Plains, NJ. | Health Technology |
- Stock Market
- Insiders
- Jay Stout
